NTIC

Business Context and Reporting Period

Company: Northern Technologies International Corporation (NTIC)
Filing Type: Form 10-K (Annual Report)
Period Ended: August 31, 2011
Business Overview: NTIC develops and markets environmentally beneficial products, primarily corrosion prevention solutions under the ZERUST brand (95% of sales) and bio-based/biodegradable polymers under the Natur-Tec brand. The company operates directly and through a network of 24 joint ventures in over 55 countries. A key strategic initiative involves expanding corrosion prevention solutions into the oil and gas industry.

Key Financial Metrics

Note: Total Debt includes current portion ($76,119) and long-term portion ($1,009,533). The company has a $3,000,000 revolving line of credit with no outstanding balance as of August 31, 2011.

Material Changes vs. Prior Period

• Revenue Growth: Consolidated net sales increased 35.7% to $19.5 million. This was driven by a 34.2% increase in ZERUST sales ($18.5M) and a 71.8% increase in Natur-Tec sales ($0.98M).
• Profitability: Net income attributable to NTIC rose 50.9% to $3.9 million. This was primarily due to a 41.3% increase in equity income from joint ventures and higher gross profit, partially offset by a 23.3% increase in total operating expenses.
• Joint Venture Performance: Joint venture sales increased 40.4% to $119.3 million, driving higher fee income and equity earnings. The German joint venture (EXCOR) and the ASEAN holding company (NTI ASEAN) remain significant contributors.
• Operating Expenses: Research and development expenses increased 30.9% to $4.36 million, reflecting continued investment in oil and gas and bioplastics technologies. Selling expenses rose 33.7% due to increased compensation and travel.
• Liquidity: Cash and cash equivalents increased by $1.49 million to $3.27 million. Working capital improved significantly to $9.09 million.

Guidance, Outlook, and Risks

• Outlook: Management anticipates continued investment in R&D ($4.3M–$4.5M for fiscal 2012) and capital expenditures (~$1.2M for fiscal 2012). Sales to the oil and gas industry are expected to remain volatile due to long sales cycles (1–2 year trials).
• Strategic Focus: Continued expansion into the oil and gas sector (e.g., Petrobras contracts) and growth of the Natur-Tec bioplastics line through new distribution agreements in India and Europe.
• Risks:
  • Joint Venture Dependency: Liquidity relies heavily on fees and dividends from joint ventures, over which NTIC has limited control regarding dividend declarations.
  • Inventory Risk: $902,507 of Natur-Tec inventory remains on the balance sheet; failure to sell at anticipated prices could necessitate future write-downs.
  • Market Conditions: Exposure to global economic downturns, particularly in the automotive sector, and the European sovereign debt crisis (60% of joint venture sales are to EU customers).
  • Competition: Intense competition in both corrosion prevention and bioplastics markets, with risks of commoditization and pricing pressure.

Investor Verification Checklist

• Joint Venture Cash Flow: Verify the timing and reliability of dividend distributions and service fees from key joint ventures (EXCOR, NTI ASEAN), as these are critical to NTIC's liquidity.
• Natur-Tec Inventory: Monitor the sell-through rate of the $902,507 Natur-Tec inventory to assess the risk of future write-downs impacting margins.
• Oil & Gas Pipeline: Track the conversion of field trials (e.g., Petrobras Phase 2) into recurring revenue, noting the long sales cycle risks.
• Debt Covenants: Confirm compliance with the fixed charge coverage ratio (minimum 1.10:1.00) required by the PNC Bank loan agreements.
• Foreign Currency Exposure: Assess the impact of Euro and other foreign currency fluctuations on reported earnings, as NTIC does not hedge these risks.